Introduction
Polycyclic aromatic hydrocarbons (PAHs) occur in the environment owing to incomplete combustion of organic fuels and cover a wide range of different compounds. Exposure to some of these compounds is known to cause cancer in mice and is also suspected to be carcinogenic in humans (1) (2) (3) (4) (5) . Although PAHs have similar structural properties, their carcinogenic potency can differ greatly. Despite that some PAHs occur in low concentrations in the environment, they can substantially contribute to the carcinogenic risk of exposure to environmental PAH mixtures. At the same time, other PAHs that occur in high concentrations in the environment are regarded as non-carcinogenic (1, 2, 6, 7) . PAHs can be carcinogenic because of their interaction with DNA and cause mutations in oncogenes or tumor suppressor genes and, thereby, initiate tumor formation (8) .
PAHs are metabolically activated by Cytochrome P450 enzymes or by peroxidases to reactive intermediates that can damage DNA by covalently binding (9) . The formation of DNA adducts by PAHs has been shown both in vitro (10) as well as in vivo (4, 11) . The DNA adduct forming potency differs between the compounds (8) and has been shown to correlate with carcinogenic potency (12) . Ross et al. (11) suggested that time-integrated DNA adduct levels are a better predictor for carcinogenicity of PAHs than DNA adduct levels at a certain time point.
Some PAHs are known to activate the Aromatic hydrocarbon receptor (Ah-receptor) (13) (14) (15) and, thereby, upregulate the expression and activity of several biotransformation enzymes, including CYP1A1 and CYP1A2 (16) (17) (18) . The ability to bind to the Ah-receptor has been suggested to reflect tumor promoting activity of PAHs (19) . Changes in the expression of genes regulated downstream of Ah-receptor binding could be considered representative for the tumor promoting potency of a PAH. The ability to bind to the Ah-receptor and induce CYP1A1 and CYP1A2 also affects the DNA binding potency of these compounds and has been suggested to determine the genotoxicity of PAHs (20) .
The toxic equivalency factor (TEF) approach is mostly used to compare the carcinogenicity of PAHs. The TEF estimates the toxicity of a compound, relative to another compound, in case of PAHs mostly to benzo [a] pyrene (B[a]P). Although based on limited information and multiple endpoints in cancer development (21, 22) , several authors have estimated a TEF for PAHs (23, 24) . Another ranking for carcinogenicity of PAHs is developed by Collins et al. (25) , who estimated a potency equivalency factor (PEF) for PAHs relative to B[a]P and based these factors on bioassay data. According to the authors, PEF is an estimation of the carcinogenic activity rather than a true carcinogenic potency.
For a better understanding of the differences in carcinogenic potency between PAHs and ultimately to improve carcinogenic risk assessment of PAHs, more knowledge is required about the biological and cellular effects induced by these compounds. To our opinion, information about alterations in gene expression following exposure of cells to a PAH might be highly valuable for risk assessment. By gene expression profiling using DNA microarray technologies, early biological changes induced by a compound on a cellular system can be investigated. Indeed this technology has proven to yield mechanistic information about the mode-of-action of the compounds (26, 27) . Furthermore, different classes of carcinogens can be discriminated from each other at gene expression level, as they induce different gene expression patterns (28, 29) .
The aim of the current study was to investigate the changes in gene expression patterns in response to several PAHs, which may help further understand the mechanism of carcinogenesis of these compounds. Therefore, we exposed human hepatoma cells (HepG2) to six PAHs selected on their diverge environmental occurrence and their range in carcinogenic potency. (30, 31) and the cells express similar biotransformation enzymes as human liver (32, 33) . These cells are a suitable model for human liver and are useful to study regulation of drug-metabolizing enzymes on gene level (34) . Cells were exposed to different concentrations of the PAHs and the effects at gene expression were studied in relation to their carcinogenic, DNA binding and Ah-receptor binding potencies. and DB[a,l]P (purity 99.6%, CAS no. 191-30-0) were obtained from SigmaAldich (Zwijndrecht, The Netherlands). 1-MPA, (purity 99%, CAS no. 832-69-9) was obtained from LGC Promchem (Teddington, UK). All chemicals were dissolved in DMSO.
Materials and methods

Chemicals
Cell culture and treatment HepG2 cells were cultured in minimal essential medium (MEM) supplemented with 1% non-essential amino acids, 1% sodium-pyruvate, 2% penicillin/ streptomycin and 10% fetal bovine serum (FBS) (all from Gibco BRL, Breda, The Netherlands) in T25 culture flasks at 37 C and 5% CO 2 . One day before treatment, cell cultures at 70-80% confluency were harvested and cells were undiluted divided among new culture flasks, in order to obtain a homogeneous cell population for each treatment. The next day, the medium was replaced with fresh medium containing 3, 10 or 30 mM of a PAH or a vehicle control (DMSO, 0.1%). The cells were exposed during 6 h, and two independent experiments were conducted. After exposure, media was removed and 1 ml Trizol (Gibco BRL, Breda, The Netherlands) was immediately added to the cells.
RNA isolation and cDNA synthesis RNA was isolated from the Trizol solutions according to the producer's manual and purified with the RNeasy mini kit (Qiagen Westburg, Leusden, The Netherlands). RNA quantity was measured on a spectrophotometer and quality was determined on a BioAnalyzer (Agilent Technologies, Breda, The Netherlands). Only RNA samples that showed clear 18S and 28S peaks were used for labeling and hybridization.
Every RNA sample was reverse transcribed into cDNA in quadruplicate with amino allyl labeled dUTP (Sigma-Aldrich, St Louis, MO) and subsequently labeled with one of the four dyes, namely Cy3, Cy5, Alexa 488 and Alexa 594. Four instead of two dyes were applied in order to reduce the variation (four related samples are on one array instead of three) and the number of arrays [as described by Staal et al. (35) ].
Microarray hybridizations
Targets were hybridized on the Human-600 Microarray (PHASE-1 Molecular Toxicology, Santa Fe, NM), containing 597 sequence verified cDNA clones from human genes, representing a number of toxicologically relevant, as well as control, genes, each printed in quadruplicate. On every array, four samples were simultaneously hybridized, each with a different fluorophore. Hybridization and washing was done according to the producers' manual as previously described (35) . The hybridization design is shown in Table I .
Microarray data analysis and data mining The microarray slides were scanned on a ScanArrayExpress (Perkin Elmer life sciences, Boston, MA). All four channels were scanned at 100% laser power and adjusted photo multiplier tube (PMT) gain, such that the signal of the highest fluorescent spots is just below the maximum measurable level. The images (10 m resolution; 16 bit tiff) were processed with ImaGene 5.0 software (Biodiscovery, Los Angeles, CA) to quantify spot signals. Abnormal spots were manually and automatically flagged and not included in the data analysis.
Data from ImaGene were transported to GeneSight software version 4.1.5 (Biodiscovery) for transformations, normalizations and analyses. For each spot, background was subtracted; flagged spots and spots with a net expression level 55 were omitted. Data were log (base 2) transformed and expression difference between exposed and control was calculated. Data normalization was done by LOWESS. Data of replicate spots were combined while omitting outliers (42 SD). Samples from each biological replicate were hybridized twice, thereby providing four hybridizations per PAH concentration (two biological replicates with two technical replicates for each replicate). Significantly modulated genes were found by a t-test between gene expression differences of each PAH concentration compared (four replicates) with selfhybridizations (four replicates) of the control samples labeled with the same dyes at P 50.05. A Holm's correction of the P-values was used to reduce false positives in these multiple tests.
Pathway analysis was done by the use of GenMAPP version 2.0 beta (Gladstone Institutes, University of California, San Fransisco, CA) and local maps from GenMAPP (human std 20040614). For each compound all modulated genes were included in the analysis. Pathways, with a Z-score 42.0 and 41 modulated gene, were assumed to be affected by the PAH.
DNA adduct analysis
After removal of the aqueous phase during RNA isolation using Trizol, the remaining phases were used for DNA isolation according to manufacturer's protocol. DNA adduct levels were determined according to the procedure originally described by Reddy and Randerath (36) with modifications described by Godschalk et al. (37) . By including samples with known DNA adduct levels (1 adduct per 10 6 , 10 7 or 10 8 nt), DNA adduct levels were quantified (detection limit 1 adduct/10 8 nt). Adduct spots on the chromatograms were located and quantified using a phosphor imager (FLA-3000, Fuji, Paris, France) and AIDA/2D densometry software.
Correlation analysis
For correlation with carcinogenic potency, we used TEF values proposed by Nisbet and LaGoy (23) After log (base 2) transformation, DNA adduct levels, TEF and IEF were correlated with the expression changes of genes differentially expressed by at least one concentration of one compound. Since after log transformation, DNA adduct formation, TEF and IEF were normally distributed (according to the Kolmogorov-Smirnov test in SPSS, P 50.05), Pearson correlation coefficients PAH-induced gene modulation and DNA adduct formation of gene expression were calculated using SPSS for windows 11.5 (SPSS, Chicago, IL).
Results
Gene expression modulation
All PAHs, except 1-MPA, induced statistically significant gene expression changes. Figure 1 shows for each compound expression changes of the genes, which were significantly modulated by that compound at least one concentration. Several genes were modulated by many compounds, for example CYP1A1, CYP1A2, VMP1, IGFBP1 and HIST1H2AL. PAH-induced gene modulation and DNA adduct formation a dose-response relation could be seen for most genes. Names, abbreviations, GenBank accession nos and gene expression differences of the 62 modulated genes are listed in Table II . Additional data files are available at http://fdgwgratsrv0401. unimaas.nl/data. Hierarchical clustering of the PAH treatments, using the 62 genes that were modulated by at least one treatment is shown in Figure 2 . The data shows that for each compound all concentrations induce similar responses, since for each compound the three concentrations are close together on the dendogram. This indicates that compound-specific gene expression profiles are induced. Also, differences and similarities between the compounds on gene expression patterns can be observed. FA and 1-MPA, which affect only a small Y.C.M.Staal et al. Fig. 2 . Hierarchical clustering of PAH treatments and genes, using the 62 that were significantly modulated by at least one of the treatments (see Table II ). Clustering with average cluster linkage and Euclidean distance metric was used. Fig. 3 . Principal component analysis of all PAH treatments using the 62 genes that were significantly modulated by at least one of the treatments (see Table II ). (Figure 3) . Comparable with clustering data, this again shows that for each PAH the three dose levels are close together implying similar response on gene level. It also shows discrimination of the PAHs indicating the presence of PAH-specific gene expression profiles.
Pathway analysis
Pathway analysis by GenMAPP of the significantly modulated genes per compound revealed several affected pathways for most compounds. An overview is shown in Table III Correlation studies DNA adduct levels for all compounds and all concentrations were correlated with the expression changes of all 62 modulated genes. Significant correlations coefficients with an R 2 4 0.4 are shown in Table V . The expression of several genes showed significant correlation with DNA adduct levels, for instance that of CYP1A1 (R ¼ 0.818, P 5 0.001).
Expression changes of significantly modulated genes were also correlated with a parameter for carcinogenic potency, TEF, and for Ah-receptor binding potency, IEF. Both parameters are based on literature data (see Materials and methods). Since for every compound we hardly observed dose-response relations in gene expression changes, the same TEF and IEF value was used for all concentrations. Significant correlation coefficients with R 2 4 0.4 are shown in Tables VI and  VII . CYP1A1, PRKCA, SLC22A3, NFKB1A, CYP1A2 and CYP2D6 appeared to correlate with all parameters, and several other genes correlated with one or two parameters.
Discussion
Differential gene expression
As modulation of gene expression in human liver cells, i.e. HepG2 cells, might reveal a toxic outcome (38), we studied this after exposure of the cells to several PAHs and related gene expression differences to parameters for genotoxicity, carcinogenic potency and Ah-receptor binding potency. All tested PAHs, except 1-MPA, were able to modulate gene expression at concentrations up to 30 mM. However, a clear dose-response was not observed. Only DB[a,l]P showed a dose-response relation in gene expression difference for many genes. This indicates that in general a maximum induction was already achieved at the lowest concentration. The fact that DNA adducts also show no clear dose-response relations suggests that saturation of metabolism of the PAH compounds is responsible for the absence of dose-response effects on gene expression. However, Bláha et al. (39) did not find a maximum induction level in the CALUX assay at concentrations similar to those we tested. Also, in liver and lung slices a doseresponse was seen up to 80 mM (40) . The difference with our results could be due to a different cell system.
Of all 600 genes on the microarray, 62 genes were found modulated by one or more compounds. Principal component and hierarchical clustering analysis using these 62 genes show that for each compound the response on gene expression profiles is grossly independent of the concentration, as all concentrations of a single compound are grouped closely together. This indicates that each compound induces a unique gene expression profile in HepG2 cells. Moreover, in the hierarchical clustering at the next higher level, the compounds are 
Pathway analysis
Pathway analysis by GenMAPP revealed that several pathways appeared to be affected by the PAHs (Table III) (20, 41, 42) . This could be due to the relative short exposure time of 6 h. Exposure to B[a]P or DB[a,l]P leads to an inhibition of genes involved in fatty acid synthesis. It has been reported that tumorigenic tissue expresses a higher level of fatty acid synthase (FAS) than normal tissue (45, 46) . Also, it has been shown that inhibition of FAS will result in apoptosis in human cancer cells (46, 47) . This would suggest that B[a]P and DB[a,l]P induce a protective response by inhibition of fatty acid synthesis. In literature we did not find a relation between PAH exposure and fatty acid synthesis pathway. However, Iwano et al. (48) previously studied the effect of 3-methylcholanthrene on the expression of several genes in HepG2 cells and found a downregulation of FASN and SCD. These enzymes are involved in fatty acid synthesis and are also downregulated in our study.
Furthermore, the Wnt signaling pathway was downregulated in response to DB[a,l]P. Genes involved in Wnt signaling (APC, b-catenin and AXIN1) are often mutated in human cancers (49, 50) . As downregulation of AXIN1 by DB[a,l]P is involved in this pathway, and as AXIN1 is a tumor suppressor gene (49) , this would suggest a tumorigenic potency of DB[a,l]P. However, no data on the influence of PAHs on the Wnt signaling pathway are known from literature.
The two pathways affected by B[a]P, G protein signaling and nucleotide metabolism, could not be related to carcinogenicity based on literature data.
Taken together, the affected pathways are generally involved in defense mechanisms, which protect against cancer. An upregulation of apoptosis would eliminate damaged cells, and by inhibiting the cell cycle and cholesterol biosynthesis, PAH-induced gene modulation and DNA adduct formation the damage due to the PAHs could be repaired. Other pathways such as fatty acid synthesis would suggest a less neoplastic phenotype of the cells after exposure to PAHs, which could be a defense mechanism of the cell against carcinogenic compounds. DB[a,h]A and DB[a,l]P are the most carcinogenic of all tested compounds, and both are also the only two that induce apoptosis. This suggests that induction of apoptosis is related to high carcinogenic potency. Other affected pathways do not seem to relate with carcinogenicity of the PAHs. As FA and 1-MPA modulate only a few or no genes significantly, they affect no biological pathways.
DNA adduct formation
PAHs have been shown to form DNA adducts in several tissues, including skin, lung and liver (10, 40, 51, 52) 
Correlation studies
We correlated the 62 genes that were modulated by at least one concentration of one compound with DNA adduct formation, TEF and IEF and found that several genes gave a high correlation coefficient. Some genes correlated with all three parameters tested, namely CYP1A1, PRKCA, SLC22A3, NFKB1A, CYP1A2 and CYP2D6. Although these genes might be used for qualitative carcinogenic risk assessment of PAHs, they are not specific for either one of the parameters. The other correlating genes might be important for a single biological function or effect, like DNA adduct levels or Ah-receptor antagonicity. Sjorgen et al. (19) related several parameters, for example Ah-receptor binding, 7-ethoxyresorufin-O-deethylase (EROD) assay data, Ames test data and carcinogenicity of PAHs and found that the affinity of PAHs to bind to the Ah-receptor correlates with carcinogenic potency of the compounds.
As expected, we found significant correlation between IEF and the gene expression of the modulated cytochome P450 enzymes. These enzymes are also involved in the metabolism of PAHs and they are known to be induced via the Ah-receptor following exposure to PAHs (14, 18) . Also, we found a correlation between DNA adduct formation and expression of GADD45, which can be explained by the DNA damage induced by the PAHs. Pathway analysis of the significantly correlating genes revealed only pathways involved in metabolism, which is probably due to the highly correlating cytochrome P450 enzymes.
Conclusion
Our data indicate that qualitative cancer risk prediction of PAH by gene expression profiling is feasible, i.e. the discrimination of carcinogenic PAH from non-carcinogenic PAH.
This may help in the characterization of risks of other PAHs for which carcinogenic potency is unknown. Additionally, some genes appeared to correlate with all three carcinogenic parameters, indicating a relationship between the expression of these genes and carcinogenicity of PAHs.
